Brief: Reviva Pharmaceuticals Announces Intent To File An IND For Brilaroxazine In Psoriasis After Promising Preclinical Data

Reviva Pharmaceuticals Holdings

11/05/2023 13:13

May 11 (Reuters) - Reviva Pharmaceuticals Holdings, Inc.
 RVPH.O :
    * REVIVA PHARMACEUTICALS ANNOUNCES INTENT TO FILE AN IND FOR
BRILAROXAZINE IN PSORIASIS AFTER PROMISING PRECLINICAL DATA
    * REVIVA PHARMACEUTICALS HOLDINGS, INC.: IND SUBMISSION FOR
BRILAROXAZINE LIPOGEL IN PSORIASIS EXPECTED IN 2024
    * REVIVA PHARMACEUTICALS.: BRILAROXAZINE TOPICAL
LIPOSOMAL-GEL
FORMULATION SHOWED PROOF-OF-CONCEPT EFFICACY IN
IMIQUIMOD-INDUCED PSORIATIC MOUSE MODEL

Source text for Eikon:  ID:nGNX7Q4l0R 
Further company coverage:  RVPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))